Clinical Scorecard: VIS-101 Shows Activity in nAMD Study
At a Glance
| Category | Detail |
|---|---|
| Condition | neovascular age-related macular degeneration (nAMD) |
| Key Mechanisms | bispecific inhibitor of VEGF-A and angiopoietin-2 |
| Target Population | patients aged 50 to 80 years with nAMD |
| Care Setting | clinical trial |
Key Highlights
- VIS-101 improved visual acuity by >10 letters on the ETDRS scale
- Reduced central subfield thickness by approximately 100 µm to 150 µm
- About two-thirds of patients required no retreatment at 4 months
- Half of patients remained retreatment-free at 6 months
- Phase 2b study planned for later in 2026
Guideline-Based Recommendations
Diagnosis
- Diagnosis of nAMD based on clinical examination and imaging
Management
- Intravitreal administration of VIS-101 after loading doses
Monitoring & Follow-up
- Assess visual acuity and retinal thickness at regular intervals
Risks
- Monitor for potential adverse effects related to intravitreal injections
Patient & Prescribing Data
38 patients with nAMD, including treatment-naïve and previously treated eyes
Randomized to receive VIS-101 at 6 mg or 3 mg after loading doses
Clinical Best Practices
- Consider patient history and previous treatments when prescribing VIS-101
- Ensure regular follow-up for visual acuity and retinal thickness assessments
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
